IN2014DN06806A - - Google Patents

Info

Publication number
IN2014DN06806A
IN2014DN06806A IN6806DEN2014A IN2014DN06806A IN 2014DN06806 A IN2014DN06806 A IN 2014DN06806A IN 6806DEN2014 A IN6806DEN2014 A IN 6806DEN2014A IN 2014DN06806 A IN2014DN06806 A IN 2014DN06806A
Authority
IN
India
Prior art keywords
mutants
oxazoline
recombinant endo
activity
glycans
Prior art date
Application number
Other languages
English (en)
Inventor
Lai Xi WANG
Wei Huang
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of IN2014DN06806A publication Critical patent/IN2014DN06806A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN6806DEN2014 2012-02-10 2013-02-11 IN2014DN06806A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597468P 2012-02-10 2012-02-10
PCT/US2013/025553 WO2013120066A1 (en) 2012-02-10 2013-02-11 Chemoenzymatic glycoengineering of antibodies and fc fragments thereof

Publications (1)

Publication Number Publication Date
IN2014DN06806A true IN2014DN06806A (enExample) 2015-05-22

Family

ID=48948091

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6806DEN2014 IN2014DN06806A (enExample) 2012-02-10 2013-02-11

Country Status (9)

Country Link
US (5) US9434786B2 (enExample)
EP (1) EP2812442B9 (enExample)
JP (1) JP6282232B2 (enExample)
CN (1) CN104220603B (enExample)
BR (1) BR112014019825B1 (enExample)
CA (1) CA2862925C (enExample)
IL (1) IL233779B (enExample)
IN (1) IN2014DN06806A (enExample)
WO (1) WO2013120066A1 (enExample)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
US9175326B2 (en) * 2011-03-03 2015-11-03 University Of Maryland, Baltimore Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae
IN2014DN06806A (enExample) * 2012-02-10 2015-05-22 Univ Maryland
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
EP3613468A1 (en) 2013-05-02 2020-02-26 Glykos Finland Oy Glycoprotein-toxic payload conjugates
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6553042B2 (ja) * 2013-09-05 2019-07-31 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 変更されたグリコシル化パターンを有するＦｃ含有分子を産生する細胞並びにその方法及び使用
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
SI3079719T1 (sl) * 2013-12-09 2019-12-31 Allakos Inc. Protitelesa proti SIGLEC-8 in postopki njihove uporabe
US9689016B2 (en) 2013-12-18 2017-06-27 Caliber Biotherapeutics, Llc Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
PL406737A1 (pl) * 2013-12-31 2015-07-06 Michał Lower Sposób przemysłowego wytwarzania białek terapeutycznych o pożądanym profilu glikozylacji
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
TWI682033B (zh) * 2014-03-17 2020-01-11 泉盛生物科技股份有限公司 製造具有經修飾的糖苷化作用之重組糖蛋白之方法
TWI687428B (zh) 2014-03-27 2020-03-11 中央研究院 反應性標記化合物及其用途
JP6750148B2 (ja) 2014-04-25 2020-09-02 公益財団法人野口研究所 糖鎖切断抗体の製造方法及び均一糖鎖抗体
JP7062361B2 (ja) * 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267051B2 (en) * 2014-05-27 2022-03-17 Academia Sinica Fucosidase from bacteroides and methods using the same
AU2015267047A1 (en) * 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
WO2015184001A1 (en) * 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
US9879042B2 (en) 2014-09-08 2018-01-30 Academia Sinica Human iNKT cell activation using glycolipids
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
ES2901173T3 (es) * 2015-01-30 2022-03-21 Academia Sinica Composiciones y procedimientos relacionados con glicoformas universales para una eficacia de anticuerpos anti-SSEA4 mejorada
JP6830576B2 (ja) * 2015-02-26 2021-02-17 東京化成工業株式会社 エンドｍ変異体、及びｎ結合型糖鎖含有化合物又はｎ結合型糖鎖含有蛋白質の製造方法
JP6744738B2 (ja) * 2015-06-29 2020-08-19 公益財団法人野口研究所 グライコシンターゼ
EP3323886B1 (en) * 2015-07-16 2020-10-21 Daiichi Sankyo Company, Limited Endos mutant enzyme
WO2017018474A1 (ja) * 2015-07-29 2017-02-02 公益財団法人野口研究所 コアフコース含有抗体の調製方法
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CN105277718B (zh) * 2015-09-29 2018-03-20 上海知先生物科技有限公司 用于恶性肿瘤相关筛查及评估的产品、应用及方法
JP6618176B2 (ja) * 2015-11-30 2019-12-11 公益財団法人野口研究所 ７糖オリゴ糖の製造方法
US11008601B2 (en) 2016-01-15 2021-05-18 University Of Maryland Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
CN116064705A (zh) * 2016-07-01 2023-05-05 第一三共株式会社 制备具有重建糖链的含Fc分子的方法
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
EP3497229A1 (en) 2016-08-10 2019-06-19 University of Maryland, College Park Designer alpha 1,6-fucosidase mutants enable direct core fucosylation of intact n-glycopeptides and n-glycoproteins
JP6731381B2 (ja) * 2016-08-10 2020-07-29 公益財団法人野口研究所 ポリエチレングリコール鎖が導入された化合物の製造方法
CN107778372B (zh) * 2016-08-22 2019-11-26 中国科学院上海药物研究所 一种寡糖连接子以及利用该寡糖连接子制备的定点连接的抗体-药物偶联物
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
US10000747B2 (en) * 2016-08-24 2018-06-19 Academia Sinica Endoglycosidase mutants for glycoprotein remodeling and methods of using it
CN110088291A (zh) * 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
CN106596827B (zh) * 2017-01-23 2019-06-07 上海知先生物科技有限公司 Gal指标在自身免疫疾病治疗敏感性和疗效评估中的应用
MX2019013137A (es) 2017-05-05 2020-07-14 Allakos Inc Metodos y composiciones para tratar enfermedades oculares alergicas.
US11459380B2 (en) * 2017-06-29 2022-10-04 University Of Maryland, College Park Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling
MX2020003125A (es) 2017-09-29 2020-10-01 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
KR20240162605A (ko) 2018-05-31 2024-11-15 다이이찌 산쿄 가부시키가이샤 항인간 tlr7 항체
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
TWI885529B (zh) 2018-07-31 2025-06-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
KR20210042120A (ko) 2018-08-06 2021-04-16 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트와 튜불린 저해제의 조합
LT3848054T (lt) 2018-09-06 2025-03-25 Daiichi Sankyo Company, Limited Ciklinių dinukleotidų darinių antikūno ir vaisto konjugatai
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
WO2020100954A1 (ja) 2018-11-14 2020-05-22 第一三共株式会社 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
KR20210102341A (ko) 2018-12-11 2021-08-19 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 parp 저해제의 조합
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
KR20210141630A (ko) 2019-03-25 2021-11-23 다이이찌 산쿄 가부시키가이샤 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
EP4010470A4 (en) * 2019-08-05 2023-08-09 Cho Pharma Inc FUSION PROTEIN FOR ANTIBODY GLYCOFORM REMODELING
AU2020420236A1 (en) * 2020-01-10 2022-09-01 Fushimi Pharmaceutical Co., Ltd. Population of antibodies comprising homogeneous antibodies each having left-right asymmetric sugar chains, and method for producing same
WO2021148955A1 (en) 2020-01-21 2021-07-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Utilization of plant protein homologues in culture media
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
TW202216208A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
CN116615248A (zh) 2020-06-24 2023-08-18 阿斯利康(英国)有限公司 抗体-药物缀合物和cdk9抑制剂的组合
TW202216209A (zh) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atm抑制劑之組合
CN116113641A (zh) 2020-09-02 2023-05-12 第一三共株式会社 新型内－β－N－乙酰氨基葡萄糖苷酶
TW202222350A (zh) 2020-10-09 2022-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及parp1選擇性抑制劑之組合
TW202227140A (zh) 2020-11-11 2022-07-16 日商第一三共股份有限公司 抗體-藥物結合物及抗SIRPα抗體之組合
TW202233249A (zh) 2020-11-12 2022-09-01 日商第一三共股份有限公司 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療
CN112442124B (zh) * 2020-12-09 2022-01-14 福州迈新生物技术开发有限公司 抗cd23蛋白单克隆抗体、细胞系及其制备方法和应用
KR20230146521A (ko) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 항체-피롤로벤조디아제핀 유도체 접합체
US20240191272A1 (en) 2021-03-31 2024-06-13 Microbiopharm Japan Co., Ltd. Method for producing antibody-drug conjugate and enzyme used for the same
MX2023014515A (es) * 2021-06-07 2024-01-29 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilacion de proteinas glucosiladas.
MX2024004048A (es) 2021-10-18 2024-04-25 Daiichi Sankyo Co Ltd Conjugado anticuerpo-farmaco anti-cd37.
CN113960232B (zh) * 2021-10-28 2024-02-20 苏州大学 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
TW202339805A (zh) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
JP2025503511A (ja) 2021-12-28 2025-02-04 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲート及びｒａｓｇ１２ｃ阻害剤の組み合わせ
WO2023136342A1 (ja) 2022-01-17 2023-07-20 第一三共株式会社 Ｔｓｐ１阻害剤
WO2023167238A1 (ja) 2022-03-02 2023-09-07 第一三共株式会社 Ｆｃ含有分子の製造方法
EP4493933A1 (en) 2022-03-16 2025-01-22 AstraZeneca UK Limited A scoring method for an anti-trop2 antibody-drug conjugate therapy
CN116925247A (zh) * 2022-03-31 2023-10-24 中国科学院上海药物研究所 一种糖探针分子、其制备方法和使用其标记核心岩藻糖基化蛋白的方法
IL316421A (en) 2022-04-27 2024-12-01 Daiichi Sankyo Co Ltd Combination of an antibody-drug conjugate with an EZH1 and/or EZH2 inhibitor
JP2025517656A (ja) 2022-05-11 2025-06-10 第一三共株式会社 腫瘍抗原に特異的である抗体と、ｃｄ４７阻害剤との組合せ
CN119300838A (zh) 2022-06-02 2025-01-10 启德医药科技（苏州）有限公司 寡糖连接子，包含寡糖连接子的连接子-负载物和糖链重塑的抗体偶联药物，其制备方法和用途
WO2024002330A1 (zh) * 2022-07-01 2024-01-04 启德医药科技（苏州）有限公司 固定化的内切糖苷酶融合蛋白及其应用
CA3262449A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Ltd COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A BISPECIFIC CHECKPOINT INHIBITOR
CN120615129A (zh) * 2022-11-09 2025-09-09 台湾浩鼎生技股份有限公司 用于抗体药物复合体工程之糖苷合成酶变体
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors
JPWO2024158047A1 (enExample) 2023-01-27 2024-08-02
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
WO2025148976A1 (zh) * 2024-01-10 2025-07-17 上海齐鲁制药研究中心有限公司 新型beta-N-乙酰氨基葡萄糖苷内切酶及其用途
WO2025238587A1 (en) 2024-05-16 2025-11-20 Daiichi Sankyo Company, Limited Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072895A (ja) * 1993-04-28 1995-01-06 Eli Lilly & Co 抗体−薬物複合体
ATE405669T1 (de) 2001-11-28 2008-09-15 Neose Technologies Inc Remodellierung von glycoproteinen unter verwendung von endoglycanasen
WO2004000802A2 (en) 2002-06-20 2003-12-31 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
US7556806B2 (en) 2002-10-11 2009-07-07 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for HIV
US20050064540A1 (en) 2002-11-27 2005-03-24 Defrees Shawn Ph.D Glycoprotein remodeling using endoglycanases
US7604804B2 (en) 2004-02-09 2009-10-20 University Of Maryland Biotechnology Institute Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120
US7728106B2 (en) 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
US20100221241A1 (en) 2005-07-06 2010-09-02 University Of Maryland Biotechnology Institute Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites
CA2663633A1 (en) 2005-09-14 2007-03-22 Lai-Xi Wang Synthetic polyvalent carbohydrates as components of microbicides
EP1957099B1 (en) * 2005-11-07 2015-03-25 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
EP2001358B1 (en) * 2006-03-27 2016-07-13 University Of Maryland, Baltimore Glycoprotein synthesis and remodeling by enzymatic transglycosylation
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
CA2655246A1 (en) 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
WO2009033670A2 (en) 2007-09-14 2009-03-19 Genovis Ab Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection
GB0821100D0 (en) * 2008-11-18 2008-12-24 Hansa Medical Ab Antibodies
ES2528321T3 (es) 2009-10-02 2015-02-06 Roche Glycart Ag Detección de a-fucosilación en anticuerpos
MX2012005006A (es) 2009-10-29 2012-06-19 Janssen Biotech Inc Variantes de glicosilacion de anticuerpos.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10851174B2 (en) 2011-03-03 2020-12-01 University Of Maryland, Baltimore Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
IN2014DN06806A (enExample) 2012-02-10 2015-05-22 Univ Maryland

Also Published As

Publication number Publication date
IL233779B (en) 2019-09-26
CN104220603A (zh) 2014-12-17
BR112014019825B1 (pt) 2021-08-24
CA2862925C (en) 2020-01-21
US10836805B2 (en) 2020-11-17
EP2812442B9 (en) 2023-02-15
CA2862925A1 (en) 2013-08-15
US11643450B2 (en) 2023-05-09
JP6282232B2 (ja) 2018-02-21
JP2015507925A (ja) 2015-03-16
US20170058040A1 (en) 2017-03-02
US20180186847A1 (en) 2018-07-05
EP2812442A1 (en) 2014-12-17
BR112014019825A8 (pt) 2017-07-11
US9845360B2 (en) 2017-12-19
US9434786B2 (en) 2016-09-06
WO2013120066A1 (en) 2013-08-15
CN104220603B (zh) 2017-06-06
US20190367570A1 (en) 2019-12-05
US10344063B2 (en) 2019-07-09
EP2812442B1 (en) 2022-11-30
IL233779A0 (en) 2014-09-30
EP2812442A4 (en) 2015-12-23
BR112014019825A2 (pt) 2017-06-20
US20150087814A1 (en) 2015-03-26
US20210061868A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IN2014DN06806A (enExample)
PH12019500518A1 (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
IL230564B1 (en) Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
MX340140B (es) Anticuerpos anti-cd40.
MX376167B (es) Ratones con complejo principal de histocompatibilidad modificado genéticamente.
IL268822A (en) Medical uses of anti-beta 7 monoclonal antibodies or fragments thereof
EA201490447A1 (ru) Эндогликозидаза из streptococcus pyogenes и способы с применением указанной эндогликозидазы
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
MY178142A (en) Anti-phf-tau antibodies and their uses
EA201291133A1 (ru) Антитела, обладающие пониженной иммуногенностью в организме человека
ZA201400559B (en) Methods for the production of a cosmetic composition from hatching fluid of salmonidae eggs and uses thereof for improving the cosmetic appearance of skin
BR112014009962A2 (pt) anticorpos humanizados para inkt
NZ703973A (en) Complex chromosome engineering for production of human antibodies in transgenic animals
EP3154583A4 (en) Human monoclonal antibodies to ganglioside gd2
WO2011011489A3 (en) Guided bayesian experimental design
IL222198A0 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
MY167208A (en) Partially Hydrolyzed Casein-Whey Nutritional Compositions for Reducing the Onset of Allergies
MX337612B (es) Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico.
MX2013003259A (es) Marco de estructura de ducha multi-pieza y metodo.
EP2984096A4 (en) SYNTHESIS OF SIALYL / FUCOSYL HUMAN MILK OLIGOSACCHARIDES
GB201306687D0 (en) Synthesis of sialylated/fucosylated oligosaccharides
WO2014130613A3 (en) Carbohydrate phosphonate derivatives as modulators of glycosylation
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
WO2013101509A3 (en) Hsp70 fusion protein conjugates and uses thereof